Table U.

Direct comparison of adverse events between the trial intervention (response-guided therapy duration boceprevir) and the trial control (matched placebo coadministered with pegylated interferon alpha plus ribavirin)

Trial	Intervention		Control		Relative risk (95% CI)
	N	Pooled (95% CI)	N	Pooled (95% CI)
Anemia
Naïve patients
Poordad et al5	182/368	49% (46%–53%)	107/363	30% (26%–33%)	1.68 (1.47–1.92)
Experienced patients
Bacon et al11	70/162	43% (38%–49%)	16/80	20% (15%–27%)	2.16 (1.55–3.02)
Neutropenia
Naïve patients
Poordad et al5	92/368	25% (22%–28%)	77/363	21% (18%–24%)	1.18 (0.98–1.42)
Rash
Naïve patients
Poordad et al5	93/368	25% (22%–29%)	83/363	23% (20%–26%)	1.11 (0.92–1.33)
Experienced patients
Bacon et al11	27/162	17% (13%–21%)	4/80	6% (3%–10%)	3.33 (1.63–6.83)
Pruritus
Naïve patients
Poordad et al5	87/368	24% (21%–27%)	98/363	27% (24%–30%)	0.88 (0.73–1.04)
Experienced patients
Bacon et al11	30/162	19% (15%–23%)	14/80	18% (12%–24%)	1.06 (0.70–1.59)

Abbreviation: CI, confidence interval.